Developer docs
API playgroundTry for free, no card

Search company profiles

Captor Therapeutics

Full company profile

uuid0007yb5

Namestring
Captor Therapeutics
Legal namestring
Captor Therapeutics S.A.
Company typeenum
Public
Founded yearint
2015
Descriptiontext

Captor Therapeutics S.A. is a clinical-stage biopharmaceutical company that leverages Targeted Protein Degradation (TPD) technology to develop therapeutics for cancer, autoimmune diseases, and neurodegenerative conditions. The company operates from dual headquarters in Wrocław, Poland (registered office) and Allschwil, Switzerland (European headquarters), and has been listed on the Warsaw Stock Exchange (ticker: CTX) since April 2021. Its core technology is the proprietary Optigrade™ drug discovery platform, which integrates protein engineering, structural biology, molecular modelling, and CRISPR/Cas9 genome editing to enable structure-guided design and rapid identification of degrader molecules against previously undruggable targets.

The product portfolio comprises multiple preclinical and clinical-stage degrader candidates, headlined by the MCL-1 Degrader (CT-03) in Phase Ia/Ib for hematological malignancies and the GSPT1/NEK7/SALL4 Triple Degrader (CT-02) in Phase 1 for hepatocellular carcinoma. Additional programs include brain-penetrant and systemic NEK7 degraders for neurodegeneration and autoimmunity, a PKCθ degrader for immunology and oncology, and the LiLis research platform exploring novel E3 ligases. Reported preclinical outcomes include near-100% target protein degradation in non-human primates, cardio-safe profiles for the MCL-1 program, and synergy with everolimus in HCC xenograft models.

The company is pre-revenue, with a revenue model oriented toward future licensing agreements, co-development partnerships, and ultimately commercialization of approved drug candidates. Capital sources include public equity raises on the Warsaw Stock Exchange (PLN 149.9 million at 2021 IPO; PLN ~66 million Series Y in March 2026), non-dilutive grants from the European Innovation Council (EIC/EIC Accelerator), NCBiR, and Poland's Medical Research Agency, plus research collaborations such as the November 2025 agreements with MD Anderson Cancer Center and an unnamed U.S. public pharmaceutical company. Reported 9-month net loss of PLN 32 million through September 2025 reflects ongoing R&D investment. Ownership is dispersed, with co-founder/CSO Michał Walczak holding 14.42% of share capital.

Short descriptiontext

Captor Therapeutics is a clinical-stage biopharmaceutical company developing Targeted Protein Degradation therapeutics for cancer, autoimmune, and neurodegenerative diseases. Listed on the Warsaw Stock Exchange (CTX), it operates from Wrocław, Poland and Basel, Switzerland, with a pipeline led by MCL-1 and GSPT1/NEK7/SALL4 degraders in Phase 1 trials.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersWroclaw, Poland
HQ citystring
Wroclaw
HQ countrystring
Poland
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
targeted protein degradation, biopharmaceutical drug discovery, cancer therapeutics development, autoimmune disease treatments, molecular glue degraders
Industry2 codes
PRIMARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Biopharmaceutical Therapeutics (Targeted Protein Degradation)
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Therapeutic Development and Commercialization
TypeLicensing Royalties
Description

Captor Therapeutics is a clinical-stage biopharmaceutical company focused on developing targeted protein degradation therapeutics. As a pre-revenue company, it does not currently have commercialized products. The company generates revenue through potential licensing agreements, co-development partnerships, and ultimately through commercialization of its drug candidates upon regulatory approval.

captortherapeutics.com
2Research Grants and Non-Dilutive Funding
TypeProfessional Services
Description

The company receives funding from public sources including the European Innovation Council (EIC), European Innovation Council Fund, National Centre for Research and Development (NCBiR), Medical Research Agency, and EIC Accelerator programs for specific R&D projects.

ceelegalmatters.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Captor Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops targeted protein degradation (TPD) therapeutics for cancer, autoimmune, and neurodegenerative diseases. Its core offering centers on the proprietary Optigrade™ drug discovery platform and a pipeline of degrader drug candidates — including MCL-1 Degrader (CT-03), GSPT1/NEK7/SALL4 Triple Degrader (CT-02), NEK7 degraders, and PKCθ degraders — designed to eliminate disease-driving proteins that traditional small-molecule inhibitors cannot address.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Near 100% NEK7 protein degradation in non-human primates (Macaca fascicularis) for over 20 hours after oral dosing
+4 more records
Product overview1 text field

Captor Therapeutics is a biopharmaceutical company leveraging Targeted Protein Degradation (TPD) technology to discover and develop breakthrough therapeutics. The company's integrated offering centers on the Optigrade™ Platform, a proprietary drug discovery engine that combines protein engineering, structural biology, and molecular modeling. The product portfolio includes multiple drug candidates in clinical development: the MCL-1 Degrader (CT-03) in Phase Ia/Ib for hematological malignancies, the GSPT1/NEK7/SALL4 Triple Degramer (CT-02) for hepatocellular carcinoma in Phase I trials, NEK7 Degraders for neuroinflammation and autoimmunity, PKCθ Degrader for immunology/oncology, and the LiLis Platform exploring new E3 ligases for TPD. The company operates from Basel, Switzerland and Wrocław, Poland.

Product and service7 records
1Optigrade™ Platform
CategoryDrug Discovery Platform
Description

Proprietary drug discovery engine integrating protein engineering, structural biology, and molecular modelling that enables structure-guided optimization of lead compound series for targeted protein degradation and rapid identification of lead-quality molecules through optimal target-ligase pair selection.

2MCL-1 Degrader (CT-03)
CategoryDrug Candidate (Oncology)
Description

Bifunctional MCL-1 degrader for hematological malignancies and solid tumors. It is a highly potent, cardio-safe degrader that induces apoptosis in cancer cells by eliminating MCL-1 protein (both anti-apoptotic and DNA damage response functions) and overcomes venetoclax resistance in AML. Near-complete MCL-1 protein degradation has been demonstrated in non-human primates without cardiotoxicity markers.

3GSPT1/NEK7/SALL4 Triple Degrader (CT-02)
CategoryDrug Candidate (Oncology)
Description

Triple degrader targeting GSPT-1, NEK7, and SALL4 proteins for treatment of hepatocellular carcinoma. Pro-drug with enhanced tissue specificity for liver and lung, demonstrating high anti-tumor activity in cell line-derived and patient-derived xenograft models and strong synergy with everolimus.

4NEK7 Degrader (Brain-Penetrant)
CategoryDrug Candidate (Neurodegenerative Disease)
Description

Brain-penetrant molecular glue degrader of NEK7 for treatment of neurodegenerative diseases including Parkinson's Disease, Alzheimer's Disease, ALS, and Huntington's Disease. Capable of crossing the blood-brain barrier and achieving near 100% protein degradation in non-human primates.

5NEK7 Degrader (Systemic)
CategoryDrug Candidate (Autoimmune Disease)
Description

Systemic molecular glue degrader targeting NEK7 for autoimmune diseases including inflammatory bowel disease (IBD), gout, and dermatological diseases. Characterized by excellent PK properties ensuring long-lasting exposure.

6PKCθ Degrader
CategoryDrug Candidate (Immunology/Oncology)
Description

Bifunctional degrader of the active form of PKCθ for applications in autoimmunity, oncology, transplantology, and metabolism. Highly selective within the PKC family and the entire kinome (KinomeScan test), and leads to 100% PKCθ degradation in mouse models of acute immune response.

7LiLis Platform (Degraders on New E3 Ligases)
CategoryTechnology Platform
Description

Research platform harnessing new E3 ligases for targeted protein degradation. Extends the range of molecular targets addressable through TPD by utilizing novel E3 ligase-recruiting molecules.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-11-17
Description

Memorandum of Understanding signed for collaboration in cancer research and development. MD Anderson is one of the world's most respected cancer centers, providing potential for significant scientific and clinical advancement of Captor's therapeutic candidates.

2U.S. Public Pharmaceutical Company
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-11-14
Description

Research Collaboration and License Option Agreement signed with a U.S. public pharmaceutical company for development of therapeutic candidates.

captortherapeutics.com
Strategic tierMajorTypeImplementation/ SI/ Consulting PartnerAnnounced on2023-10-11
Description

Service contracts concluded for Phase I clinical trials for the CT-01 project (hepatocellular carcinoma). ICON is a leading CRO providing clinical development services.

4Ono Pharmaceutical Co., Ltd.
Strategic tierFormerTypeStrategic or Co-development PartnerAnnounced on2022-11-07
Description

Collaboration agreement signed for development of therapeutic candidates. The collaboration was subsequently terminated in March 2025 as reported in current report RB ESPI 19/2025.

captortherapeutics.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Arvinas is a clinical-stage biotechnology company pioneering PROTAC targeted protein degradation for cancer and other diseases. It is the most direct public comparable to Captor, with similar platform technology, clinical-stage oncology degraders, and a comparable BD/licensing commercial model.

TypeDirect peer
Description

Foghorn is a clinical-stage oncology biotech using a chromatin-based target-discovery engine to develop precision medicines. Comparable to Captor in scale, clinical maturity (Phase I), and platform-based approach to expanding the druggable target universe in oncology.

TypeEmerging player
Description

BioTheryX is a biotechnology company developing targeted protein degraders (molecular glues and bifunctional degraders) for cancer and inflammatory diseases. Comparable to Captor as a TPD-focused peer with overlapping modality and disease strategy, though earlier-stage.

TypeDirect peer
Description

C4 Therapeutics is a clinical-stage biotech developing degrader-based medicines (including MonoDAC and BiDAC platforms) for cancer and other diseases. Direct competitor to Captor in protein degradation technology with overlapping target selection and clinical-stage maturity.

TypeBroad incumbent
Description

Novartis is a global pharmaceutical company with internal targeted protein degradation capabilities (including acquired programs) and a major oncology franchise. It is a relevant incumbent peer given its overlapping TPD investments and its position as a likely strategic partner/acquirer for Captor-type assets.

TypeEmerging player
Description

Cullinan Oncology is a clinical-stage biopharmaceutical company focused on oncology with a diversified pipeline of development candidates. Comparable to Captor in size, clinical maturity, and oncology-focused pipeline strategy, though using a broader modality mix (not TPD-only).

TypeBroad incumbent
Description

Pfizer is a global pharmaceutical company with an active internal protein degradation effort (including via the Arvinas-partnered ARV-471) and broad oncology/immunology franchises. It is a relevant incumbent peer because of its deep TPD R&D footprint and frequent role as a major-player BD counterparty in the degrader space.

TypeDirect peer
Description

Monte Rosa is a clinical-stage biotech developing molecular glue degraders for cancer and autoimmune diseases. It is a closely comparable peer to Captor in degrader class (molecular glues vs Captor's bifunctional degraders), disease focus, and clinical stage.

TypeDirect peer
Description

Kymera is a clinical-stage biopharmaceutical company developing targeted protein degraders across immunology-inflammation and oncology. It is directly comparable to Captor in modality (TPD), stage (Phase I/II), and disease focus (cancer and immune-mediated diseases).

TypeEmerging player
Description

Amphista is a European biotechnology company developing next-generation targeted protein degradation therapies leveraging novel mechanisms beyond CRBN. Comparable to Captor as a TPD platform peer focused on differentiated E3 ligase biology, with overlapping technology positioning though earlier-stage.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Captor Therapeutics

Biopharmaceutical Therapeutics (Targeted Protein Degradation)captortherapeutics.com

Captor Therapeutics is a clinical-stage biopharmaceutical company developing Targeted Protein Degradation therapeutics for cancer, autoimmune, and neurodegenerative diseases. Listed on the Warsaw Stock Exchange (CTX), it operates from Wrocław, Poland and Basel, Switzerland, with a pipeline led by MCL-1 and GSPT1/NEK7/SALL4 degraders in Phase 1 trials.

What Captor Therapeutics does

Captor Therapeutics S.A. is a clinical-stage biopharmaceutical company that leverages Targeted Protein Degradation (TPD) technology to develop therapeutics for cancer, autoimmune diseases, and neurodegenerative conditions. The company operates from dual headquarters in Wrocław, Poland (registered office) and Allschwil, Switzerland (European headquarters), and has been listed on the Warsaw Stock Exchange (ticker: CTX) since April 2021. Its core technology is the proprietary Optigrade™ drug discovery platform, which integrates protein engineering, structural biology, molecular modelling, and CRISPR/Cas9 genome editing to enable structure-guided design and rapid identification of degrader molecules against previously undruggable targets.

The product portfolio comprises multiple preclinical and clinical-stage degrader candidates, headlined by the MCL-1 Degrader (CT-03) in Phase Ia/Ib for hematological malignancies and the GSPT1/NEK7/SALL4 Triple Degrader (CT-02) in Phase 1 for hepatocellular carcinoma. Additional programs include brain-penetrant and systemic NEK7 degraders for neurodegeneration and autoimmunity, a PKCθ degrader for immunology and oncology, and the LiLis research platform exploring novel E3 ligases. Reported preclinical outcomes include near-100% target protein degradation in non-human primates, cardio-safe profiles for the MCL-1 program, and synergy with everolimus in HCC xenograft models.

The company is pre-revenue, with a revenue model oriented toward future licensing agreements, co-development partnerships, and ultimately commercialization of approved drug candidates. Capital sources include public equity raises on the Warsaw Stock Exchange (PLN 149.9 million at 2021 IPO; PLN ~66 million Series Y in March 2026), non-dilutive grants from the European Innovation Council (EIC/EIC Accelerator), NCBiR, and Poland's Medical Research Agency, plus research collaborations such as the November 2025 agreements with MD Anderson Cancer Center and an unnamed U.S. public pharmaceutical company. Reported 9-month net loss of PLN 32 million through September 2025 reflects ongoing R&D investment. Ownership is dispersed, with co-founder/CSO Michał Walczak holding 14.42% of share capital.

Captor Therapeutics firmographics

Firmographics
Name
Captor Therapeutics
Legal name
Captor Therapeutics S.A.
Website
https://captortherapeutics.com
Company type
Public
Founded year
2015
Operating status
Operating
Headcount range
51–100 employees
Short description
Captor Therapeutics is a clinical-stage biopharmaceutical company developing Targeted Protein Degradation therapeutics for cancer, autoimmune, and neurodegenerative diseases. Listed on the Warsaw Stock Exchange (CTX), it operates from Wrocław, Poland and Basel, Switzerland, with a pipeline led by MCL-1 and GSPT1/NEK7/SALL4 degraders in Phase 1 trials.
Ownership category
akta.pro rank

Captor Therapeutics industry classification

Industry
Product category
Biopharmaceutical Therapeutics (Targeted Protein Degradation)
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Targeted protein degradation
  • Biopharmaceutical drug discovery
  • Cancer therapeutics development
  • Autoimmune disease treatments
  • Molecular glue degraders

Where Captor Therapeutics is headquartered

Location

Headquarters

HQ city
Wroclaw
HQ country
Poland
HQ region
Europe

Offices2 records

Markets served

Captor Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Therapeutic Development and Commercialization: Captor Therapeutics is a clinical-stage biopharmaceutical company focused on developing targeted protein degradation therapeutics. As a pre-revenue company, it does not currently have commercialized products. The company generates revenue through potential licensing agreements, co-development partnerships, and ultimately through commercialization of its drug candidates upon regulatory approval.
  2. Research Grants and Non-Dilutive Funding: The company receives funding from public sources including the European Innovation Council (EIC), European Innovation Council Fund, National Centre for Research and Development (NCBiR), Medical Research Agency, and EIC Accelerator programs for specific R&D projects.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

Captor Therapeutics product offering

Product offering

Core offering

Captor Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops targeted protein degradation (TPD) therapeutics for cancer, autoimmune, and neurodegenerative diseases. Its core offering centers on the proprietary Optigrade™ drug discovery platform and a pipeline of degrader drug candidates — including MCL-1 Degrader (CT-03), GSPT1/NEK7/SALL4 Triple Degrader (CT-02), NEK7 degraders, and PKCθ degraders — designed to eliminate disease-driving proteins that traditional small-molecule inhibitors cannot address.

Product overview

Captor Therapeutics is a biopharmaceutical company leveraging Targeted Protein Degradation (TPD) technology to discover and develop breakthrough therapeutics. The company's integrated offering centers on the Optigrade™ Platform, a proprietary drug discovery engine that combines protein engineering, structural biology, and molecular modeling. The product portfolio includes multiple drug candidates in clinical development: the MCL-1 Degrader (CT-03) in Phase Ia/Ib for hematological malignancies, the GSPT1/NEK7/SALL4 Triple Degramer (CT-02) for hepatocellular carcinoma in Phase I trials, NEK7 Degraders for neuroinflammation and autoimmunity, PKCθ Degrader for immunology/oncology, and the LiLis Platform exploring new E3 ligases for TPD. The company operates from Basel, Switzerland and Wrocław, Poland.

Differentiator

Problem solved

Functional benefit

Products and services

  • Optigrade™ Platform Proprietary drug discovery engine integrating protein engineering, structural biology, and molecular modelling that enables structure-guided optimization of lead compound series for targeted protein degradation and rapid identification of lead-quality molecules through optimal target-ligase pair selection.
  • MCL-1 Degrader (CT-03) Bifunctional MCL-1 degrader for hematological malignancies and solid tumors. It is a highly potent, cardio-safe degrader that induces apoptosis in cancer cells by eliminating MCL-1 protein (both anti-apoptotic and DNA damage response functions) and overcomes venetoclax resistance in AML. Near-complete MCL-1 protein degradation has been demonstrated in non-human primates without cardiotoxicity markers.
  • GSPT1/NEK7/SALL4 Triple Degrader (CT-02) Triple degrader targeting GSPT-1, NEK7, and SALL4 proteins for treatment of hepatocellular carcinoma. Pro-drug with enhanced tissue specificity for liver and lung, demonstrating high anti-tumor activity in cell line-derived and patient-derived xenograft models and strong synergy with everolimus.
  • NEK7 Degrader (Brain-Penetrant) Brain-penetrant molecular glue degrader of NEK7 for treatment of neurodegenerative diseases including Parkinson's Disease, Alzheimer's Disease, ALS, and Huntington's Disease. Capable of crossing the blood-brain barrier and achieving near 100% protein degradation in non-human primates.
  • NEK7 Degrader (Systemic) Systemic molecular glue degrader targeting NEK7 for autoimmune diseases including inflammatory bowel disease (IBD), gout, and dermatological diseases. Characterized by excellent PK properties ensuring long-lasting exposure.
  • PKCθ Degrader Bifunctional degrader of the active form of PKCθ for applications in autoimmunity, oncology, transplantology, and metabolism. Highly selective within the PKC family and the entire kinome (KinomeScan test), and leads to 100% PKCθ degradation in mouse models of acute immune response.
  • LiLis Platform (Degraders on New E3 Ligases) Research platform harnessing new E3 ligases for targeted protein degradation. Extends the range of molecular targets addressable through TPD by utilizing novel E3 ligase-recruiting molecules.

Quantifiable outcome

  • Near 100% NEK7 protein degradation in non-human primates (Macaca fascicularis) for over 20 hours after oral dosing
  • +4 more outcomes

Companies that use Captor Therapeutics

Customer profile

Segments2 records

Ideal customer profiles2 records

Captor Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature7 records

Captor Therapeutics partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered major and former.

  • The University of Texas MD Anderson Cancer CentermajorStrategic or Co-development Partner · 17 November 2025Memorandum of Understanding signed for collaboration in cancer research and development. MD Anderson is one of the world's most respected cancer centers, providing potential for significant scientific and clinical advancement of Captor's therapeutic candidates.
  • U.S. Public Pharmaceutical CompanymajorStrategic or Co-development Partner · 14 November 2025Research Collaboration and License Option Agreement signed with a U.S. public pharmaceutical company for development of therapeutic candidates.
  • ICON Clinical Research LimitedmajorImplementation/ SI/ Consulting Partner · 11 October 2023Service contracts concluded for Phase I clinical trials for the CT-01 project (hepatocellular carcinoma). ICON is a leading CRO providing clinical development services.
  • Ono Pharmaceutical Co., Ltd.formerStrategic or Co-development Partner · 7 November 2022Collaboration agreement signed for development of therapeutic candidates. The collaboration was subsequently terminated in March 2025 as reported in current report RB ESPI 19/2025.

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

Captor Therapeutics competitors and assessment

Company assessment

Direct peers

  • Arvinas: Arvinas is a clinical-stage biotechnology company pioneering PROTAC targeted protein degradation for cancer and other diseases. It is the most direct public comparable to Captor, with similar platform technology, clinical-stage oncology degraders, and a comparable BD/licensing commercial model.
  • Foghorn Therapeutics: Foghorn is a clinical-stage oncology biotech using a chromatin-based target-discovery engine to develop precision medicines. Comparable to Captor in scale, clinical maturity (Phase I), and platform-based approach to expanding the druggable target universe in oncology.
  • C4 Therapeutics: C4 Therapeutics is a clinical-stage biotech developing degrader-based medicines (including MonoDAC and BiDAC platforms) for cancer and other diseases. Direct competitor to Captor in protein degradation technology with overlapping target selection and clinical-stage maturity.
  • Monte Rosa Therapeutics: Monte Rosa is a clinical-stage biotech developing molecular glue degraders for cancer and autoimmune diseases. It is a closely comparable peer to Captor in degrader class (molecular glues vs Captor's bifunctional degraders), disease focus, and clinical stage.
  • Kymera Therapeutics: Kymera is a clinical-stage biopharmaceutical company developing targeted protein degraders across immunology-inflammation and oncology. It is directly comparable to Captor in modality (TPD), stage (Phase I/II), and disease focus (cancer and immune-mediated diseases).

Emerging players

  • BioTheryX: BioTheryX is a biotechnology company developing targeted protein degraders (molecular glues and bifunctional degraders) for cancer and inflammatory diseases. Comparable to Captor as a TPD-focused peer with overlapping modality and disease strategy, though earlier-stage.
  • Cullinan Oncology: Cullinan Oncology is a clinical-stage biopharmaceutical company focused on oncology with a diversified pipeline of development candidates. Comparable to Captor in size, clinical maturity, and oncology-focused pipeline strategy, though using a broader modality mix (not TPD-only).
  • Amphista Therapeutics: Amphista is a European biotechnology company developing next-generation targeted protein degradation therapies leveraging novel mechanisms beyond CRBN. Comparable to Captor as a TPD platform peer focused on differentiated E3 ligase biology, with overlapping technology positioning though earlier-stage.

Broad incumbents

  • Novartis: Novartis is a global pharmaceutical company with internal targeted protein degradation capabilities (including acquired programs) and a major oncology franchise. It is a relevant incumbent peer given its overlapping TPD investments and its position as a likely strategic partner/acquirer for Captor-type assets.
  • Pfizer: Pfizer is a global pharmaceutical company with an active internal protein degradation effort (including via the Arvinas-partnered ARV-471) and broad oncology/immunology franchises. It is a relevant incumbent peer because of its deep TPD R&D footprint and frequent role as a major-player BD counterparty in the degrader space.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Captor Therapeutics social profiles

Digital presence

Captor Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Captor Therapeutics leadership team

Management profile

Number of profiles

Profiles4 records

Captor Therapeutics funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Captor Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Captor Therapeutics

What does Captor Therapeutics do?

Captor Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops targeted protein degradation (TPD) therapeutics for cancer, autoimmune, and neurodegenerative diseases. Its core offering centers on the proprietary Optigrade™ drug discovery platform and a pipeline of degrader drug candidates — including MCL-1 Degrader (CT-03), GSPT1/NEK7/SALL4 Triple Degrader (CT-02), NEK7 degraders, and PKCθ degraders — designed to eliminate disease-driving proteins that traditional small-molecule inhibitors cannot address.

Is Captor Therapeutics a public or private company?

Captor Therapeutics is a public company. It is classified as public and is currently operating.

When was Captor Therapeutics founded?

Captor Therapeutics was founded in 2015. It employs 51 to 100 people.

Where is Captor Therapeutics based?

Captor Therapeutics is headquartered in Wroclaw, Poland, in the Europe region.

How does Captor Therapeutics make money?

Two revenue lines are on record. Therapeutic Development and Commercialization is the primary driver. The others are research Grants and Non-Dilutive Funding.

Who are Captor Therapeutics's main competitors?

Direct peers on record are Arvinas, Foghorn Therapeutics, C4 Therapeutics, Monte Rosa Therapeutics and Kymera Therapeutics. Emerging players are BioTheryX, Cullinan Oncology and Amphista Therapeutics. Broad incumbents are Novartis and Pfizer.

Does Captor Therapeutics have an API?

No public API is recorded for Captor Therapeutics.

What industry is Captor Therapeutics in?

Captor Therapeutics's product category is Biopharmaceutical Therapeutics (Targeted Protein Degradation). Its primary akta.pro industry code is HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery), with a secondary code of HLAAAIAC, Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
NatureUniting the protein degradation generationCaptor Therapeutics is advancing a dual pipeline of molecular glues and bifunctional degraders using structural biology. Its lead asset CT-01 targets hepatocellular carcinoma, with first-in-human trials planned in 2023. The company expects to begin testing CT-03 in 2024 and is seeking partnerships.GlobeNewswireCaptor Therapeutics Publishes Q1 2023 Financial ResultsCaptor Therapeutics published its Q1 2023 results, reporting R&D spend of nearly PLN 16 million with PLN 5.6 million in non-dilutive funding. The company's lead asset CT-01 is on track for clinical trial application authorization in Q3 2023, and its collaboration with Ono Pharmaceuticals is progressing according to plan.BioSpaceCaptor Therapeutics Announces Three-Year Strategic ObjectivesCaptor Therapeutics announced its 2023-2025 strategic objectives to become a clinical-stage TPD leader, initiating trials for CT-01 and CT-03 in 2023 and 2024. The plan budgets about $74m, financed by existing cash, grants, and collaborations, with potential US NASDAQ listing.GlobeNewswireCaptor Therapeutics Announces Three-Year Strategic ObjectivesCaptor Therapeutics announced its 2023-2025 strategic objectives to become a clinical-stage TPD leader, initiating clinical trials for CT-01 and CT-03 in 2023 and 2024. The plan includes advancing early pipeline assets and expanding the Optigrade platform, with a budget of approximately $74m financed by existing cash and potential capital raising.GlobeNewswireCaptor Therapeutics Nominates the Molecular Glue CPT-6281 as Drug Candidate to Enter CTA/IND-Enabling Studies for the Treatment of Hepatocellular CarcinomaCaptor Therapeutics selected CPT-6281 as its first drug candidate for hepatocellular carcinoma, targeting ERF3A, SALL4, and an undisclosed neo-substrate. The company will initiate large-scale synthesis and expects to enter clinical trials in 2023.PR NewswireSosei Heptares and Captor Therapeutics Enter Strategic Technology Collaboration Focused on Targeted GPCR Degradation as Novel Approach for Drug DesignSosei Heptares and Captor Therapeutics have entered a strategic technology collaboration focused on discovering and developing novel small molecules that target the degradation of disease-associated G protein-coupled receptors (GPCRs) for treating a broad range of diseases. The collaboration will initially focus on a GPCR implicated in gastrointestinal disorders, combining Sosei Heptares' structure-based drug design platform with Captor's proprietary targeted protein degradation (TPD) Optigrade™ platform. Under the agreement, both companies will jointly conduct discovery and development programs and co-own any resulting products, with Sosei Heptares supporting initial R&D costs.